<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375255</url>
  </required_header>
  <id_info>
    <org_study_id>5051-101</org_study_id>
    <nct_id>NCT03375255</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy (DMD)</brief_title>
  <official_title>A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK)
      of 5 escalating doses of SRP-5051 administered as a single dose to patients with DMD amenable
      to exon 51 skipping treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Adverse Events (AEs)</measure>
    <time_frame>Up to 14 Weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical trial patient, which does not necessarily have a causal relationship with the investigational drug. An AE can, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurs during or after administration of the study drug whether or not considered related to the study drug.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>SRP-5051</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be sequentially assigned to receive one of the 5 escalating dose levels of SRP-5051 on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-5051</intervention_name>
    <description>Single dose of SRP-5051 administered as an intravenous (IV) infusion.</description>
    <arm_group_label>SRP-5051</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a genetic diagnosis of DMD and an out-of-frame deletion mutation of the DMD gene
             amenable to exon 51 skipping treatment

          -  Has been on a stable dose of oral corticosteroids for at least 12 weeks prior to study
             drug administration, or has not received corticosteroids for at least 12 weeks prior
             to study drug administration

        Exclusion Criteria:

          -  Has a left ventricular ejection fraction (LVEF) less than (&lt;) 40 percent (%) based on
             an echocardiogram (ECHO) performed within 3 months prior to Screening or at the
             Screening visit

          -  Has a QTcF &gt;= 450 millisecond (msec) on the Screening electrocardiogram (ECG)

          -  Initiation or change of dosing (except for modifications to accommodate changes in
             weight) within 12 weeks prior to Screening for any of the following: angiotensin
             converting enzyme (ACE) inhibitors, angiotensin receptor blocking agents (ARBs),
             beta-blockers, potassium

          -  Requires antiarrhythmic and/or antidiuretic therapy for heart failure

          -  Forced vital capacity (FVC) &lt;40% of predicted value within 3 months of screening or at
             the Screening visit

          -  Known kidney disease or had an acute kidney injury within 6 months

          -  Treatment with eteplirsen or drisapersen within 6 months prior to Screening, or any
             experimental gene therapy for the treatment of DMD at any time
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Rakhade, MD,PHD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>+1-888-727-3782</phone>
    <email>medinfo@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Sam</last_name>
      <phone>310-825-3264</phone>
      <email>CHSam@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norane Shehab</last_name>
      <phone>352-294-8705</phone>
      <email>norane.shehab@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NW FL Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shae Colbert</last_name>
      <phone>850-934-1299</phone>
      <email>scolbert@nwflcrg.com</email>
    </contact>
    <investigator>
      <last_name>Weldon Mauney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han C Phan, MD</last_name>
      <phone>678-883-6897</phone>
      <email>info@rarediseaseresearch.com</email>
    </contact>
    <investigator>
      <last_name>Han C Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Oswald</last_name>
      <phone>312-227-3019</phone>
      <email>toswald@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Kuntz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiley Higss</last_name>
      <phone>913-945-9922</phone>
      <email>ksims2@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Minchew</last_name>
      <phone>913-945-9920</phone>
      <email>hminchew@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Statland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Bird, RN,BSN,CCRC</last_name>
      <phone>614-722-2699</phone>
      <email>lauren.bird@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jerry R Mendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M Monahan</last_name>
      <phone>412-692-5176</phone>
      <email>jennifer.monahan@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Hoda Z Abdel-Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>Exon Skipping</keyword>
  <keyword>DMD</keyword>
  <keyword>Exon 51</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

